Infusion-Related Reactions With Ublituximab in the Phase 3 **ULTIMATE | and || Studies in Relapsing Multiple Sclerosis**

Edward J. Fox, MD, PhD,¹ Lawrence Steinman, MD,² Hans-Peter Hartung, MD,³⁻⁶ Enrique Alvarez, MD, PhD,⁷ Peiqing Qian, MD,⁸ Sibyl Wray, MD,⁹ Derrick Robertson, MD,¹⁰ DeRen Huang, MD, PhD,¹¹ Krzysztof Selmaj, MD, PhD,^{12,13} Daniel Wynn, MD,¹⁴ Koby Mok, PhD,¹⁵ Denise Campagnolo, MD,¹⁵ Bruce A. C. Cree, MD, PhD, MAS¹⁶

¹Central Texas Neurology Consultants, Round Rock, TX; ²Stanford University, Stanford, CA; ³Heinrich Heine University Düsseldorf, Düsseldorf, Germany; ⁴Brain and Mind Centre, University of Sydney, Sydney, Australia; ⁵Medical University of Vienna, Vienna, Austria; ⁶Palacký University Olomouc, Olomouc, Czech Republic; ⁷University of Colorado, Aurora, CO; ⁸Swedish Medical Center, Seattle, WA; ⁹Hope Neurology, Knoxville, TN; ¹⁰University of South Florida, Tampa, FL; ¹¹Center for Multiple Sclerosis, Mount Carmel Health System, Westerville, OH; ¹²Center of Neurology, Lodz, Poland; ¹³University of Warmia and Mazury, Olsztyn, Poland; ¹⁴Consultants in Neurology, Northbrook, IL; ¹⁵TG Therapeutics, New York, NY; ¹⁶UCSF Weill Institute for Neurosciences, San Francisco, CA

OBJECTIVE

 To further characterize the time course, severity, and type of infusion-related reactions (IRRs) with ublituximab

KEY FINDINGS

- In pooled analyses of the ULTIMATE studies, 96.6% of participants completed ublituximab infusions without interruption, and 94.6% completed Doses 2-5 maintenance infusions within 1 hour±5 minutes
- 43% of ublituximab-treated participants had an IRR at Dose 1, the proportion of participants experiencing an IRR markedly decreased to <10.0% for all subsequent infusions, and 69.5% did not have an IRR recurrence
- 78.8% of Dose 1 and 69.2% of Dose 2 IRRs with ublituximab occurred during the infusion period or within 1 hour post infusion
- The administration route of premedications (oral, intravenous [IV], intramuscular [IM], or mixed) did not impact the frequency of IRRs

CONCLUSIONS


- IRRs were the prevailing adverse event (AE) with ublituximab in ULTIMATE I and II; the vast majority were mild to moderate in severity
- Most IRRs occurred at Dose 1, markedly decreased with subsequent infusions, and had minimal impact on infusion completion
- The proportion of ublituximab-treated participants with pyrexia, chills, headache, and influenza-like illness was 9.5%, 7.9%, 7.5%, and 5.9%, respectively

REFERENCES 1. Le Garff-Tavernier M, et al. Leukemia. 2014;28(1):230-233. 2. Babiker HM, et al. Expert Opin Investig Drugs. 2018;27(4):407-412. 3. Steinman L, et al. Presented at: ECTRIMS; October 13-15, 2021; Virtual. Oral presentation 117. 4. Ferrara C, et al. Proc Natl Acad Sci U S A. 2011;108(31):12669-12674. 5. Sun Y, et al. J Biol Chem. 2021;297(1):100826. 6. de Romeuf C, et al. Br J Haematol. 2008;140(6):635-643. 7. Fox E, et al. Mult Scler. 2021;27(3):420-429.

ACKNOWLEDGMENTS The authors thank the participants and their families for participating in the ULTIMATE I and II studies. The authors also thank Apollo Medical Communications for providing medical writing and editorial support, which was funded by TG Therapeutics. The ULTIMATE I and II studies were sponsored by TG Therapeutics.

BACKGROUND

- Ublituximab is a novel, next generation monoclonal antibody that targets a unique epitope of CD20 and is glycoengineered for enhanced antibodydependent cellular cytotoxicity (Figure 1)^{1,2}
- Ublituximab is administered in lower doses and with shorter infusion times compared with other currently infused anti-CD20 therapies³
- ULTIMATE I (NCT03277261) and ULTIMATE II (NCT03277248) are identical, Phase 3, randomized, multicenter, double-blind, active-control, double-dummy studies evaluating the efficacy and safety of ublituximab vs teriflunomide in participants with relapsing multiple sclerosis (RMS)³
- ULTIMATE I and II met their primary endpoint, demonstrating a statistically significant reduction in annualized relapse rate for ublituximab compared with teriflunomide as well as significant improvements in the number of gadoliniumenhancing T1 lesions and the number of new/enlarging T2 lesions³



RESULTS

- The total number of infusions was 2644 for ublituximab and 2637 for placebo. Overall, 96.6% of ublituximab infusions were completed without interruption (Table 1)
- The proportion of participants with IRRs was 47.7% and 12.2% in the ublituximab and placebo infusion groups, respectively³
- In the ublituximab-treated group, 89.7% of participants completed Dose 1 infusion without interruption within 4 hours 15 minutes, and 94.6% completed their maintenance infusions (Doses 2-5) without interruption within 1 hour±5 minutes (Table 1)

Table 1. Infusion Completion					
	Teriflunomide (n=548)	Ublituximab (n=545)			
Number of infusions, mean±SD	4.8±0.68	4.8±0.62			
Total number of started infusions, n (%)	2637 (100)	2644 (100)			
Total number of completed infusions, n (%)	2629 (99.7)	2629 (99.4)			
Total number of completed infusions without interruption, n (%)	2623 (99.5)	2554 (96.6)			
Total number of completed infusions with interruption, n (%)	6 (0.2)	75 (2.8)			
Dose 1 infusion					
Total number of started infusions, n (%)	548 (100)	545 (100)			
Total number of completed infusions within 4 h 15 min without interruption, n (%)	532 (97.1)	489 (89.7)			
Doses 2-5 infusions					
Total number of started infusions, n (%)	2089 (100)	2099 (100)			
Total number of completed infusions within 1 h±5 min without interruption, n (%)	2015 (96.5)	1985 (94.6)			
Pooled analysis. Safety population. SD, standard deviation.					

Participants With IRR at Dose 1

• 30.1% (164/545) of ublituximab-treated participants experienced an IRR at Dose 1 only and 13.2% (72/545) experienced an IRR at Dose 1 and ≥1 subsequent dose

Participants With 1 IRR

• Of all ublituximab-treated participants with an IRR, 67.7% (176/260) had 1 IRR only; of these, the majority (93.2% [164/176]) experienced the IRR during Dose 1

Participants With >1 IRR

• In ublituximab-treated participants with >1 IRR, 85.7% (72/84) experienced the first IRR during Dose '

ADCC, antibody-dependent cellular cytotoxicity; NK, natural killer.

METHODS

- progressive) with disease activity³

- or equivalent) and corticosteroid (dexamethasone 10-20 mg or equivalent)
- physician's discretion
- Participants could receive oral, IV, IM, or mixed routes of premedication

Timing of Dose 1 and Dose 2 IRRs

• 78.8% of Dose 1 and 69.2% of Dose 2 IRRs with ublituximab occurred during the infusion period or within 1 hour post infusion (Table 2)

Table 2. Timing of IRRs				
	Teriflunomide (n=548)	Ublituximab (n=545)		
Dose 1 IRRs, % (n/N)				
Participants with an IRR ^a	9.7 (53/548)	43.3 (236/545)		
During the 4-hour infusion period ^b	32.1 (17/53)	69.9 (165/236)		
≤1 hour post infusion ^b	15.1 (8/53)	8.9 (21/236)		
Dose 2 IRRs, % (n/N)				
Participants with an IRR ^a	3.1 (17/545)	9.6 (52/540)		
During the 1-hour infusion period ^b	35.3 (6/17)	48.1 (25/52)		
≤1 hour post infusion ^b	11.8 (2/17)	21.2 (11/52)		

ased on the number of participants who received that infusion. ^bPercentage based on the number of participants with an IRR at that infusion; IRRs without an exact start time were excluded. Pooled analysis. Safety population. R. infusion-related reaction.

• The proportion of ublituximab-treated participants with pyrexia, chills, headache, and influenza-like illness was 9.5%, 7.9%, 7.5%, and 5.9%, respectively (Table 3)

Table 3. IRRs ^a						
	Teriflunom	ide (n=548)	Ublituximab (n=545)			
TEAE preferred term, n (%)	All Grades	Grade ≥3	All Grades	Grade ≥3		
Participants with any IRR TEAE	67 (12.2)	1 (0.2)	260 (47.7)	15 (2.8)		
Pyrexia	4 (0.7)	0	52 (9.5)	1 (0.2)		
Chills	3 (0.5)	0	43 (7.9)	1 (0.2)		
Headache	12 (2.2)	0	41 (7.5)	0		
Influenza-like illness	5 (0.9)	0	32 (5.9)	0		
IRR	3 (0.5)	0	27 (5.0)	1 (0.2)		
Hyperthermia	2 (0.4)	0	25 (4.6)	0		
Nausea	2 (0.4)	0	18 (3.3)	0		
Sinus tachycardia	3 (0.5)	0	17 (3.1)	0		
Body temperature increased	2 (0.4)	0	15 (2.8)	0		
Lymphocyte count decreased	1 (0.2)	0	15 (2.8)	9 (1.7)		
Throat irritation	0	0	14 (2.6)	0		
Tachycardia	4 (0.7)	0	13 (2.4)	0		
Pain in extremity	0	0	8 (1.5)	0		
Tremor	0	0	8 (1.5)	0		
Erythema	0	0	7 (1.3)	0		
Dizziness	2 (0.4)	0	6 (1.1)	0		
Hypersensitivity	1 (0.2)	0	6 (1.1)	0		
Oropharyngeal pain	2 (0.4)	0	6 (1.1)	0		
Pruritus	0	0	6 (1.1)	0		

^aTreatment-emergent; occurring in >1% in either group. Pooled analysis. Safety population. IRR, infusion-related reaction; TEAE, treatment-emergent adverse event.

• ULTIMATE I and II enrolled a total of 1094 adult participants from 10 countries with a diagnosis of RMS (relapsing-remitting or secondary-

• Participants received ublituximab 450 mg administered by 1-hour IV infusion every 24 weeks (following Day 1 infusion of 150 mg over 4 hours [Dose 1] and Day 15 infusion of 450 mg over 1 hour [Dose 2]) or teriflunomide 14 mg oral once daily for 96 weeks³

• The teriflunomide group received placebo infusions; the ublituximab group received oral placebo³

• Participants received premedication 30-60 minutes prior to each dose of ublituximab or IV placebo: antihistamine (diphenhydramine 50 mg

• Acetaminophen (650 mg or equivalent) was not included in the recommended premedication for Dose 1 and was restricted to participants who experienced fever or pyrexia after Dose 1, as clinically warranted. Additional medication for adverse reactions could be used at the

• A 1-hour postinfusion observation period was not required for participants who did not experience IRRs during Dose 1 and Dose 2 • IRRs were defined as infusion-related AEs reported during or within 24 hours of the end of an infusion


• Pooled investigator-reported IRR data from both studies were analyzed. IRRs were evaluated in the safety population of all participants who received ≥ 1 dose of study drug (ublituximab or teriflunomide, with corresponding placebos)

- Most IRRs in the ublituximab-treated group were mild to moderate in severity and decreased in frequency with subsequent dosing³
- One participant experienced a Grade 4 IRR (anaphylaxis) with ublituximab at the Dose 2 infusion following two Grade 1 IRRs at Dose 1 (both reported as influenza-like syndrome); the Dose 2 infusion was interrupted and drug withdrawn. All IRRs resolved
- Another participant experienced a Grade 4 IRR reported as lymphocyte count decreased (0.1×10⁹/L) at the Dose 1 infusion. The IRR was reported as serious and related to ublituximab. No treatment or dosage change was required, and the outcome was reported as recovered/ resolved. The participant continued into the study extension phase with no additional IRRs
- In addition to the participant described above, 5 other participants discontinued ublituximab due to an IRR (Table 4). Of the additional cases, all were Grade 2 and one was considered serious

Table 4. Participants Discontinuing Ublituximab Due to an IRR						
Participant	Preferred term	Grade	Serious (Y/N)	Outcome		
1 (described above)	Anaphylactic reaction	4	Υ	Recovered/resolved		
2	IRR	2	Ν	Recovered/resolved		
3	Hypersensitivity	2	Y	Recovered/resolved		
4	Myocardial ischemia	2	Ν	Recovered/resolved		
5	Toxic skin eruption	2	Ν	Recovered/resolved		
6	Bronchospasm	2	Ν	Recovered/resolved		

IRR, infusion-related reaction.

• The administration route of premedications (oral, IV, IM, or mixed) did not impact the frequency of IRRs (Figure 2)





Copies of this poster obtained by QR code are for reference permission of the authors and study spons